A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Fischer S, Götze T, Omlin A, Baird R, Dawson K, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. JCO Precis Oncol 2022; 6:e2200006.
01.11.2022
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
01.11.2022
JCO Precis Oncol 2022; 6:e2200006
Fischer Stefanie, Götze Thorsten O, Omlin Aurelius, Baird Richard D, Dawson Keith M, Zitt Christof, Arany Zita, Tresch Gaby, Fiedler Ulrike, Jeger Simone, Fung Samson, Legenne Philippe, Leupin Nicolas, Schneeweiss Andreas, Fremd Carlo
Weiter
